PLK4 inhibitor exhibits antitumor effect and synergizes sorafenib via arresting cell cycle and inactivating Wnt/ß-catenin pathway in anaplastic thyroid cancer.

Zhu, Wei; Xie, Bin

Zhu, Wei; Xie, Bin.

Affiliation

Zhu W; Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Xie B; Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.

Cancer Biol Ther ; 24(1): 2223383, 2023 12 31.

Article in En | MEDLINE | ID: mdl-37351847

Subject(s)

Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Humans; Sorafenib/pharmacology; Thyroid Carcinoma, Anaplastic/drug therapy; Thyroid Carcinoma, Anaplastic/genetics; Glycogen Synthase Kinase 3 beta/metabolism; beta Catenin/metabolism; Cell Line, Tumor; Cell Cycle; Cell Division; Wnt Signaling Pathway; Apoptosis; Thyroid Neoplasms/pathology; Cell Proliferation; Protein Serine-Threonine Kinases/genetics

Key words

anaplastic thyroid cancer; malignant behaviors; polo-like kinase 4 inhibitor; sorafenib; synergistic effect

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thyroid Neoplasms / Thyroid Carcinoma, Anaplastic Limits: Humans Language: En Journal: Cancer Biol Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2023 Document type: Article Affiliation country: China Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google